Traditionally, clinical trials have relied on paper-based consent forms to obtain participant approval. But this approach creates significant challenges. Administrative staff may misplace forms or spend unnecessary time on repetitive consent procedures, and participants often struggle to understand complex medical terminology.
As clinical trial models continue to evolve, particularly with the growth of decentralized and hybrid approaches, these issues have become more pronounced, underscoring the need for digital alternatives. Electronic consent (eConsent) offers a modern solution that provides far more than a simple digital replacement for paper forms. It integrates data management and compliance tools to ensure consent collection is accurate, secure and regulatory-compliant. Features like signature validation, timestamping and version tracking minimize errors, reduce compliance risks and streamline the entire process.
eConsent is designed to enhance usability and comprehension to serve both participants and research teams. For participants, it translates complex medical and legal language into accessible formats, such as videos, voiceovers and interactive glossaries, making trial details easier to understand across diverse backgrounds. For research teams, it provides flexibility to manage a wide range of study designs, from simple trials to complex multi-arm studies, while also streamlining re-consenting and version control to reduce administrative burden.
Another important benefit is accessibility. eConsent makes participation easier by working seamlessly on the devices people are most comfortable with, from smartphones and tablets to computers. This inclusivity helps bridge generational divides; while older adults have historically lagged behind younger groups in technology adoption, the gap is narrowing. According to Pew Research, 61% of adults aged 65 and older now own a smartphone, up from just 13% in 2012. By working with commonly used devices, eConsent enhances participation, comprehension and inclusion across all demographic groups.
Finally, eConsent platforms are built to meet global regulatory requirements so sponsors and researchers can maintain consistent, compliant consent processes across diverse trial types and geographies.
Why eConsent is critical in decentralized trials
The expansion of decentralized clinical trials (DCTs) has highlighted the inherent limitations of paper-based consent. Without a digital solution, trial sites face logistical hurdles, such as mailing documents, arranging in-person meetings and manually managing protocol amendments. These inefficiencies slow progress and strain resources. Paper forms also increase the risk of consent-related protocol deviations, including missing signatures, outdated versions or incomplete re-consenting when protocols change. While these errors may seem minor, they often lead to costly delays and corrective actions that disrupt trial timelines.
eConsent directly addresses these challenges. By enabling real-time education, secure remote authentication and automated version control, it eliminates logistical bottlenecks while also reducing human error. Built-in safeguards, such as automated signature prompts, timestamp tracking and version control, ensure compliance and data integrity. At the same time, participants benefit from multimedia tools and clear explanations that enhance their understanding of study procedures and promote adherence to trial protocols. In this way, eConsent creates measurable value for both participants and research teams, from improved comprehension to reduced administrative burden.
Industry evidence reinforces these advantages. A McKinsey report explains that today’s biggest barriers to efficient trials are not scientific expertise or funding but rather the pace of recruitment and mounting operational strain on sites. By streamlining processes, eConsent accelerates trial start-up, improves recruitment productivity and supports higher success rates. Similarly, a systematic review published in JMIR examined 35 studies involving more than 13,000 participants and found that eConsent consistently improved comprehension, usability and satisfaction compared with paper consent. Participants engaged more deeply with study materials, often spending more time reviewing key information, while early evidence also pointed to reduced site workload, a critical benefit for trial operations.
Advantages of eConsent across the ecosystem
eConsent enables integration across the broader ecosystem of technologies like ePRO, telehealth and EHRs. As clinical trial organizations transition to digital workflows, eConsent offers data continuity, accessibility and regulatory alignment across participants, research teams and regulators:
- Meaningful engagement and access
-
-
- Empowered participation. Interactive tools, such as videos, quizzes, voiceovers and plain language summaries, help participants better understand the study, leading to more meaningful engagement and higher-quality consent.
- Cross-generational access. With digital adoption rising across all age groups, eConsent offers features like audio-visual consent, large-font displays and remote workflows for legally authorized representatives. These are especially valuable in geriatric, pediatric and emergency care studies.
- Remote accessibility. Participants can review forms at their own pace, ask questions via integrated chat or video tools and sign documents remotely, reducing travel and broadening trial access.
-
- Efficiency and scalability
-
-
- Operational efficiency. Automated version control simplifies re-consenting when protocols change, reducing manual tracking and administrative burden.
- Support for complex study designs. eConsent platforms accommodate master protocols and multi-stage studies, streamlining document management in fields like oncology and neurology.
-
- Transparency and trust
-
- Improved audit trails. Digital records capture when consent was given, how materials were reviewed and whether comprehension checks were completed, strengthening regulatory compliance and oversight.
Overcoming barriers to eConsent adoption
Despite its clear advantages, transitioning to eConsent can present challenges. Some clinical sites hesitate to adopt new technologies due to concerns about training requirements, implementation costs or integration with existing systems. Others worry about navigating varying regulatory standards across regions or ensuring the security of electronic signatures.
These challenges are being actively addressed. eConsent providers now offer customizable, globally compliant solutions that adapt to local requirements while maintaining consistency across studies. In parallel, regulatory bodies, such as the FDA and EMA, have issued guidance supporting digital consent, emphasizing its role in improving participant understanding and reducing errors.
Organizations that adopt eConsent early not only overcome these hurdles but also position themselves for competitive advantage, reducing study start-up delays, enhancing recruitment and building stronger participant trust.
eConsent as a strategic asset for digital transformation
As clinical research evolves, eConsent is moving beyond a point solution and emerging as a cornerstone of modern trial design. Increasingly recognized by regulators, sponsors and sites alike, it is no longer just a tool for digitizing consent but a driver of digital transformation across the research ecosystem.
Looking forward, eConsent has the potential to serve as the gateway to broader patient engagement platforms. When integrated with tools like electronic patient-reported outcomes, telehealth services, electronic health records and wearable devices, eConsent can enable continuous communication, real-time data capture and more responsive care. This convergence will deliver a seamless participant experience, improve data quality and strengthen trial outcomes.
For organizations still relying on paper-based consent, the message is clear: now is the time to modernize. As participants increasingly expect flexibility, transparency and digital access, eConsent has shifted from “nice-to-have” to become a strategic necessity. It equips trials to meet rising patient expectations, eliminate operational bottlenecks and remain competitive in an increasingly decentralized and data-driven world.
About the Author:
Vinita Navadgi is senior director of product management, digital products and solutions at IQVIA., a technology leader focused on innovation in clinical research and advancement of drugs. With over 25 years of technology expertise, she is passionate about accelerating clinical research and the patient consenting process by leveraging digitally transformative technologies while offering intuitive user experiences.
Filed Under: clinical trials, Drug Discovery
